EndoPredict’s accurate low-risk assessment can help patients consider safely forgoing chemotherapy

The Myriad myRisk^® Hereditary Cancer test is a 28-gene panel that identifies an elevated risk for eight hereditary cancers

BRACAnalysis ^® is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. BRCAmutations are responsible for the majority of hereditary breast and ovarian cancers. People with a mutation in either the BRCA1 or BRCA2 gene have risks of up to 87 percent for developing breast cancer and 39-63 percent for developing ovarian cancer by age 70. Mutation carriers previously diagnosed with cancer also have a significantly increased risk of developing a second primary cancer. In fact, patients with these types of mutations have an up to 64 percent chance of developing a second breast cancer by age 70.

Prolaris is a genomic test developed to aid healthcare professionals in predicting prostate cancer aggressiveness in conjunction with clinical parameters such as Gleason score and PSA.

Zeesan's Saliva Sample Collection Kit provides an all-in-one system for the collection, stabilization and transportation of saliva sample for DNA/RNA preservation. The preservation solution is non-toxic, leakage-proof and collection involves only 3 steps. The sample collection kit has CFDA approval for clinical use in China and CE marked for IVD use in Europe.

Zeesan's Automatic and Manual Extraction Kit is intended to be used by professional users, such as technicians and physicians who are trained in molecular biological techniques. The kit provides high-quality RNA that is suitable for downstream applications, such as amplification or other enzymatic reactions.   Intended Use:  1) NMPA approved in China for clinical use 2) CE marked for IVD use in Europe